To further examine the role of IL-17A in Type II diabetes-mediated diabetic retinopathy, and the efficacy of anti-IL-17A in Type II diabetic mice, an in vivo treatment regimen was designed in Leprdb (db/db) diabetic mice. This evidence concerns the gene IL17A and type 2 diabetes mellitus.